An 8.5-month-old boy with Wiskott-Aldrich syndrome received a sibling matched bone marrow transplant from his healthy non-identical twin brother. The donor had primary human herpes virus 6 (HHV-6) infection around the time of bone marrow donation. The recipient had hepatitis in the first week and then developed fever and rash on day 18. Skin biopsy was shown to have HHV-6 antigen and his peripheral blood leukocytes were HHV-6 DNA positive. He engrafted on day 18 but the ANC dropped from 5.5 × 10 9 /l (day 23) to 0.48 × 10 9 /l (day 34) with persistent HHV-6 DNAemia. Bone marrow on day 35 was positive for HHV-6 DNA. He was treated with G-CSF and ganciclovir with good response. He later had pneumonitis which was treated empirically with foscarnet, ceftazidime and clarithromycin. Keywords: foscarnet; ganciclovir; HHV 6; infection; myelosuppression; Wiskott-Aldrich syndrome Human herpes virus 6 (HHV-6) has been implicated in causing various complications in patients receiving bone marrow transplantation, 1 including fever with skin rashes, 2 interstitial pneumonitis, 3,4 fatal encephalitis, 5 and bone marrow suppression. 6 The virus involved has been shown to be almost exclusively the B variant 7,8 and the infectious complications were usually the result of reactivation of the HHV-6 rather than a primary infection. [1] [2] [3] [4] [5] [6] We report a male infant with Wiskott-Aldrich syndrome who had a primary infection with HHV-6 resulting from infusion of bone marrow from his non-identical twin brother who had roseola infantum at the time of marrow donation.
with a birth weight of 3.63 kg. He has a healthy non-identical twin brother. Neonatal alloimmune thrombocytopenia and congenital infection were excluded and the thrombocytopenia persisted despite treatment with intravenous immunoglobulin (1 g/kg/dose × 2) and prednisolone, in the referring hospital. Bone marrow examination was compatible with consumptive thrombocytopenia. He developed eczema over his flexor areas, lower trunk and buttocks at 6 months of age. Since then several episodes of bloody diarrhea, scalp abscesses as well as suppurative otitis externa have occurred. He also had oral and nasal mucosal bleeding which have progressed in terms of severity and frequency. He was referred to us at 7 months of age for further investigation and management.
His platelet count was 15 to 23 × 10 9 /l. The mean platelet volume was 4 to 5 fl. His platelets were positive for CD41, CD42b and CD61, ruling out deficiencies of glycoprotein IIb/IIIa and glycoprotein Ib/IX complex. His serum IgG was high at 1640 mg/dl (normal range for age 331-871 mg/dl), 9 IgA high at 100 mg/dl (normal range for age 11-93 mg/dl) and IgM low normal at 52 mg/dl (normal range for age 34-198 mg/dl). He was seropositive for antiHBs antibody, poliovirus neutralization antibody type 1 (1:1024), type 2 (1:8) and type 3 (1:4) and anti-tetanus antibody (0.58 IU/ml). He was seronegative for HHV-6 antibody. Peripheral blood lymphocyte subsets by flow cytometry showed CD19-positive cells at 24.6% and 1406/l (normal range for age 700-1700/l), 10 CD3-positive cells at 43.9% and 2514/l (normal range for age 1800-3300/l), CD4-positive cells at 32.8% and 1879/l (normal range for age 900-2300/l), CD8-positive cells at 9.2% and 527/l (normal range for age 700-1500/l). Lymphocyte proliferation to PHA, ConA and PWM was within normal limits.
The boy was diagnosed to have Wiskott-Aldrich syndrome and his non-identical healthy twin brother was found to be fully HLA-matched with him. In view of the several life-threatening bleeding episodes, splenectomy was performed before the BMT. However, he developed focal seizures of the left upper limb and left angle of the mouth, secondary to intracerebral bleeding as confirmed by CT scan of the brain during the post-splenectomy period. Fortunately there were no permanent neurological sequelae.
He received an allogeneic bone marrow infusion at the age of 8.5 months after conditioning with busulfan (20 mg/kg), cyclophosphamide (200 mg/kg) and anti-thymocyte globulin (120 mg/kg). GVHD prophylaxis was with cyclosporin A and the standard short course of methotrexate. The nucleated cell dose was 2.8 × 10 8 /kg and plasma reduction was carried out for minor blood group mismatch (O → B). The donor had a high fever for 2 days prior to the marrow harvest. His fever subsided on the morning of harvest with the appearance of a fine erythematous rash. To minimize possible transmission and effects of a viral infection, intravenous immunoglobulin (1 g/kg) was given to the recipient after marrow infusion. This infection of the donor was subsequently confirmed to be primary HHV-6 infection by demonstration of HHV-6 DNA in the donor's peripheral blood by PCR, as well as a significant rise of his serum IgG against HHV-6 from 1 in 10 to 1 in 400 in an immunofluorescent test. 11 In order to monitor HHV-6 infection in the recipient, weekly PCR for HHV-6 DNA was performed using his peripheral blood leukocytes (PBL). 11 His liver transaminases rose from day 3, peaked at day 8 (ALT 324 IU/l, AST 418 IU/l) and remained elevated until day 24. His PBL first became HHV-6 DNA positive on day 17. Neutrophil engraftment occurred on day 18 and he had fever and a diffuse rash over the back and face around the time of engraftment. He was given a short course of steroids (2 mg/kg/day methylprednisolone) for a presumptive diagnosis of grade III skin GVHD. There was no diarrhea and the serum bilirubin remained within normal limits throughout. Skin biopsy revealed features compatible with acute GVHD and HHV-6 antigen was shown in histiocytes by immunohistology 12 ( Figure 1 ) using monoclonal antibody 6.1 (kindly provided by Dr J Fox, University College, UK) and HHV-6 DNA by PCR. His absolute neutrophil count (ANC) rose to a peak of 5.5 × 10 9 /l on day 23 but then started to decrease progressively to 0.48 × 10 9 /l on day 34. In view of the persistently positive HHV-6 DNA in PBL and the otherwise unexplained myelosuppression, he was started on both G-CSF and ganciclovir (5 mg/kg 12 hourly) on day 34. A bone marrow done on day 35 was also positive for HHV-6 DNA but no viral antigens were detectable by immunohistology. The neutropenia recovered rapidly on a combination of G-CSF and ganciclovir, with an ANC of 2.9 × 10 9 /l on day 39. Subsequently, he developed fever and cough associated with lung infiltrates, especially in the right upper lobe. Since HHV-6 DNA in PBLs remained positive, ganciclovir was changed to foscarnet on day 43. Viral DNA in PBL became undetectable on day 45, but the lung infiltrates persisted. Stopping the foscarnet on day 62 was followed by a transient reappearance of HHV-6 DNA in PBL on day 66, but subsequent specimens were negative. Because of persisting cough and lung infiltrates, a bronchoscopy and bronchoalveolar lavage were done on day 92, but failed to reveal any etiological agent. No evidence of HHV-6 antigen was seen in the bronchoalveolar lavage fluid by immunofluorescence. Axillary lymph node biopsy (day 97) only showed dermatopathic lymphadenopathy and was negative for HHV-6 antigen and DNA by immunohistochemistry and PCR, respectively. Apart from the foscarnet, he was also given ceftazidime and clarithromycin empirically for the pneumonititis. His cough gradually resolved and he was discharged asymptomatic on day 112.
HHV-6 DNA from the donor's blood, the recipient's bone marrow and multiple PBL specimens was tested with a HHV-6 variant typing PCR 13 and shown to be variant B. Both donor and recipient were seronegative for CMV pretransplant, and serial post-transplant PBL were negative for CMV DNA by PCR. The post-transplant PBL specimens were also all negative for HHV-7 DNA by PCR.
Discussion
The 8.5-month-old donor had a typical clinical course of roseola infantum at the time of bone marrow harvest. Our local seroepidemiological data indicated that 70 and 80% of children would have had HHV-6 infection by 1 and 2 years of age, respectively.
14 Moreover, seroconversion was demonstrated during the time of fever and rash, indicating the donor had a primary infection with HHV-6 during the marrow harvest. It is then highly likely that the recipient contracted the HHV-6 infection from the infusion of donor marrow which contained HHV-6. The HHV-6 infection in the recipient was a primary infection because he was seronegative for HHV-6 and his PBLs were negative for HHV-6 DNA by PCR before transplantation. Therefore, we had a unique opportunity to chart the course of a primary HHV-6 infection within the context of BMT. Most, if not all of the previous reports of HHV-6 infection in BMT patients were from reactivation rather than primary infection. [1] [2] [3] [4] [5] [6] There was, however, one patient who contracted primary HHV-6 infection following liver transplantation from a seropositive donor 15 and he had fever, convulsions and hepatitis associated with the HHV-6 viraemia and seroconversion.
The incubation period of roseola infantum in immunocompetent individuals has previously been documented to range from 5-15 days. 16 Our recipient had evidence of hepatitis starting from as early as the first week which lasted for over 3 weeks. This might have been due to direct infusion of a significant viral load of HHV-6 from the marrow donation but other causes were equally possible. Although HHV-6 DNA was not detectable in the PBLs at this time, the severe neutropenia after BMT may have resulted in a falsely negative result. HHV-6 was detected in the recipient's PBLs at the time of engraftment when he had fever and a skin rash. The skin biopsy showed evidence of both GVHD and HHV-6 infection, the relative contribution by each being open to speculation. Five days after neutrophil engraftment, he started to have evidence of bone marrow suppression resulting in a significant drop of the ANC to only 0.48 × 10 9 /l by day 34. Bone marrow examination done on day 35 also demonstrated presence of HHV-6 DNA by PCR while the peripheral blood had evidence of an extended period of HHV-6 DNAemia from day 17 to day 41. This association in time, together with absence of an alternative explanation for the myelosuppression would suggest HHV-6 was the cause. 6 He was then started on both G-CSF and ganciclovir with good response of the neutropenia. However, he then developed evidence of pneumonitis with persistent HHV-6 DNAemia. It was not certain whether HHV-6 was the etiological agent for the lung infiltrates. Nevertheless foscarnet was substituted for ganciclovir because foscarnet would have antiviral activity against both A and B variants of HHV-6 while ganciclovir may only have activity against the B variant. 17 The variant typing was only done after the clinical events resolved. Throughout the course of BMT, he had no evidence of encephalitis.
In conclusion, our recipient had primary HHV-6 infection resulting from infusion of HHV-6 containing marrow and this infection resulted in fever, skin rash and bone marrow suppression after engraftment. The early onset hepatitis and late pneumonitis may or may not have been HHV-6 associated. His myelosuppression showed a good clinical response to ganciclovir.
